Atlas Trials

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

Clinical trial NCT06994507 · RECRUITING

Trial details

NCT number
NCT06994507
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Start date
2025-08-01
Primary completion
2026-09-01
Enrollment
352

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.